tetano
Editor, Senior Moderator
Intern Med
. 2022;61(7):1067-1069.
doi: 10.2169/internalmedicine.8851-21. Epub 2022 Apr 1.
Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
Makoto Yamakawa[SUP] 1 [/SUP], Keiichi Nakahara[SUP] 1 [/SUP], Toshihito Nakanishi[SUP] 2 [/SUP], Toshiya Nomura[SUP] 1 [/SUP], Mitsuharu Ueda[SUP] 1 [/SUP]
Affiliations
Abstract
After BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination, a 30-year-old man developed bilateral lateral gaze palsy, diplopia, absent tendon reflexes, and ataxic gait. Serum anti-GQ1b and anti-GT1a immunoglobulin G (IgG) antibodies were strongly positive. Based on those findings, he was diagnosed with Miller Fisher syndrome (MFS). Intravenous immunoglobulin therapy was administered, and his symptoms fully recovered within approximately 3 months. To the best of our knowledge, this is the first report to describe the development of MFS after COVID-19 mRNA vaccination.
Keywords: COVID-19; Miller Fisher syndrome; SARS-CoV-2; adverse event; vaccine.
. 2022;61(7):1067-1069.
doi: 10.2169/internalmedicine.8851-21. Epub 2022 Apr 1.
Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
Makoto Yamakawa[SUP] 1 [/SUP], Keiichi Nakahara[SUP] 1 [/SUP], Toshihito Nakanishi[SUP] 2 [/SUP], Toshiya Nomura[SUP] 1 [/SUP], Mitsuharu Ueda[SUP] 1 [/SUP]
Affiliations
- PMID: 35370249
- DOI: 10.2169/internalmedicine.8851-21
Abstract
After BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination, a 30-year-old man developed bilateral lateral gaze palsy, diplopia, absent tendon reflexes, and ataxic gait. Serum anti-GQ1b and anti-GT1a immunoglobulin G (IgG) antibodies were strongly positive. Based on those findings, he was diagnosed with Miller Fisher syndrome (MFS). Intravenous immunoglobulin therapy was administered, and his symptoms fully recovered within approximately 3 months. To the best of our knowledge, this is the first report to describe the development of MFS after COVID-19 mRNA vaccination.
Keywords: COVID-19; Miller Fisher syndrome; SARS-CoV-2; adverse event; vaccine.